Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.

Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Abstract: A pharmaceutical preparation comprising {circle around (?)} A2-73 substantially free of ? A2-73. This invention further includes a method treating Alzheimer's disease in a subject in need of such treatment by the method of administering a therapeutically effective amount of {circle around (?)} A2-73 substantially free of ? A2-73. This invention yet further includes a method of classifying cells as to sigma receptor type by the method of exposing said cells to a detectable amount of {circle around (?)} A2-73 substantially free of ? A2-73 and determining the level of sigma receptor binding.

Abstract: The uses of guanidine hydrochloride as a drug for treating cancers/tumors. Guanidine hydrochloride can destroy the formation of hydrogen bonds by polar molecules on the surface of cancer cells and the macromolecules taken up, thereby demonstrating that guanidine hydrochloride can inhibit the uptake by cancer cells. The present invention provides new uses of guanidine hydrochloride in the treatment of subjects suffering from cancers/tumors and prevention of recurrence after cancer operation. The dose of guanidine hydrochloride administration is 10-35 mg/kg a day. The hydrochloride dose of the guanidine has a significant inhibitory effect on the uptake of DNA by cancer cells, which in turn can effectively inhibit the proliferation of cancer cells; besides, the inhibition rate of liver cancer tumors 9 days after the injection of guanidine hydrochloride drugs can reach 42%, and the inhibition rate of lung cancer tumors 7 days after the injection of guanidine hydrochloride drugs reach 56.8%.

Abstract: Provided herein are novel amide prodrug forms of pharmaceutically active agents useful for central nervous system disorders.

Abstract: Compounds of the formula I in which R1 denotes A, Ar, Cyc, Het, COA or CN, R2 denotes SO2A, SOA, SA, SO2NHA, SO2NA2, S(?NH,?O)A, S(?NH)2A, NO2, Hal, CN, A, Het1, COOH or COOA, R3 denotes H or Hal, R4 denotes H or Hal, n denotes 1, 2 or 3, A denotes unbranched or branched alkyl having 1-6 C-atoms, Cyc denotes cyclic alkyl with 3 to 7 C-atoms, Ar denotes phenyl, Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, Het1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, and Hal denotes F, Cl, Br, or I, are inhibitors of HIF-2?, and can be employed for the treatment of diseases such as cancer.

Abstract: Compositions and methods relating to induction of cell death such as in cancer cells are disclosed. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds in connection with modification of procaspases such as procaspase-3 are disclosed. In various embodiments, the compounds and compositions are capable of activation of procaspase-3.

Abstract: Methods for the treatment of leptomeningeal disease in a pediatric patient. The leptomeningeal disease may be leptomeningeal, disseminated, and/or multicentric disease (LDM) and may be associated with one or more primary CNS tumors or one or more low-grade gliomas (LGGs). The method includes administering to a patient a plurality of extraneous antineoplastons.

Abstract: Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

Abstract: 7-hydroxymatairesinol and a composition thereof for ameliorating the neurodegenerative disorders, in particular the disorders associated with dopaminergic neurons loss, such as the Parkinson's disease.

Abstract: Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula I and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors: In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Abstract: The present disclosure provides for compounds useful for the treatment or prevention of disorders with an etiology associated with or comprising excessive cytokine or chemokine release. The compounds are also useful for the treatment of cancer, inflammatory disorders and disorders associated with an increased stability or translation of mRNA which has an mRNA instability sequence.

Abstract: The present disclosure relates to a method of preparing a furan monomer having a bifunctional hydroxymethyl group (2, 5-bis(hydroxymethyl) furan (BHMF)). The method includes converting furfuryl alcohol to a low-molecular weight furan mixture extracting and purifying the furan monomer having a bifunctional hydroxymethyl group from the low-molecular weight furan mixture.

Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.

Abstract: Medicaments for use in treating T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, breast cancer, ovarian cancer, melanoma, lung cancer, pancreatic cancer, glioblastoma, sarcoma, desmoid tumors, adenoid cystic carcinoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, or skin cancer in a patient comprising combination therapy with 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof, and 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. X is selected from the group consisting of O and H; R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, and R2 is selected from (C1 to C10) alkyl, (C1 to C10) alkenyl, (C1 to C10) alkynyl, (C3 to C10) cycloalkyl, and (C5 to C10) cycloalkenyl, and NR3aR3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburg virus.

Abstract: Provided is a process for the formation of nitrated compounds by the nitration of hydrocarbon compounds with dilute nitric acid. Also provided are processes for preparing industrially useful downstream derivatives of the nitrated compounds, as well as novel nitrated compounds and derivatives, and methods of using the derivatives in various applications.

Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, Z1, W, Z2 and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.